Literature DB >> 31362850

Defining and Modulating 'BRCAness'.

Andrea K Byrum1, Alessandro Vindigni2, Nima Mosammaparast3.   

Abstract

The concept of 'BRCAness' defines the pathogenesis and vulnerability of multiple cancers. The canonical definition of BRCAness is a defect in homologous recombination repair, mimicking BRCA1 or BRCA2 loss. In turn, BRCA-deficient cells utilize error-prone DNA-repair pathways, causing increased genomic instability, which may be responsible for their sensitivity to DNA damaging agents and poly-(ADP)-ribose polymerase inhibitors (PARPis). However, recent work has expanded the mechanistic basis of BRCAness, to include defects in replication fork protection (RFP). Here, we broaden the definition of BRCAness to include RFP and regulatory mechanisms that cause synthetic lethality with PARPis. We highlight these recent discoveries, which include mechanisms of RFP regulation, DNA damage checkpoint proteins, as well as kinases that regulate BRCA1/2 function. Importantly, many of these emerging mechanisms may be targeted for inhibition with small molecule inhibitors, thus inducing BRCAness in a much larger subset of BRCA-proficient tumors, with significant translational potential.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  BRCA1; BRCA2; PARP; chemotherapy resistance; homologous recombination; replication fork protection

Mesh:

Substances:

Year:  2019        PMID: 31362850     DOI: 10.1016/j.tcb.2019.06.005

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   20.808


  38 in total

Review 1.  Synthetic Lethality through the Lens of Medicinal Chemistry.

Authors:  Samuel H Myers; Jose Antonio Ortega; Andrea Cavalli
Journal:  J Med Chem       Date:  2020-11-02       Impact factor: 7.446

2.  EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion.

Authors:  Antonio Marzio; Emma Kurz; Jennifer M Sahni; Giuseppe Di Feo; Joseph Puccini; Shaowen Jiang; Carolina Alcantara Hirsch; Arnaldo A Arbini; Warren L Wu; Harvey I Pass; Dafna Bar-Sagi; Thales Papagiannakopoulos; Michele Pagano
Journal:  Cell       Date:  2021-12-27       Impact factor: 41.582

3.  Triple negative breast cancer: approved treatment options and their mechanisms of action.

Authors:  Aditya Mandapati; Kiven Erique Lukong
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-17       Impact factor: 4.322

Review 4.  Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use.

Authors:  Rachel Abbotts; Anna J Dellomo; Feyruz V Rassool
Journal:  Cancers (Basel)       Date:  2022-05-26       Impact factor: 6.575

5.  Ex vivo analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma.

Authors:  Rami Mäkelä; Ville Härmä; Nibal Badra Fajardo; Greg Wells; Zoi Lygerou; Olle Sangfelt; Juha Kononen; Juha K Rantala
Journal:  Oncotarget       Date:  2021-05-25

6.  ADP-ribosyltransferases, an update on function and nomenclature.

Authors:  Bernhard Lüscher; Ivan Ahel; Matthias Altmeyer; Alan Ashworth; Peter Bai; Paul Chang; Michael Cohen; Daniela Corda; Françoise Dantzer; Matthew D Daugherty; Ted M Dawson; Valina L Dawson; Sebastian Deindl; Anthony R Fehr; Karla L H Feijs; Dmitri V Filippov; Jean-Philippe Gagné; Giovanna Grimaldi; Sebastian Guettler; Nicolas C Hoch; Michael O Hottiger; Patricia Korn; W Lee Kraus; Andreas Ladurner; Lari Lehtiö; Anthony K L Leung; Christopher J Lord; Aswin Mangerich; Ivan Matic; Jason Matthews; George-Lucian Moldovan; Joel Moss; Gioacchino Natoli; Michael L Nielsen; Mario Niepel; Friedrich Nolte; John Pascal; Bryce M Paschal; Krzysztof Pawłowski; Guy G Poirier; Susan Smith; Gyula Timinszky; Zhao-Qi Wang; José Yélamos; Xiaochun Yu; Roko Zaja; Mathias Ziegler
Journal:  FEBS J       Date:  2021-07-29       Impact factor: 5.622

7.  The dystonia gene THAP1 controls DNA double-strand break repair choice.

Authors:  Kenta Shinoda; Dali Zong; Elsa Callen; Wei Wu; Lavinia C Dumitrache; Frida Belinky; Raj Chari; Nancy Wong; Momoko Ishikawa; Andre Stanlie; Trisha Multhaupt-Buell; Nutan Sharma; Laurie Ozelius; Michelle Ehrlich; Peter J McKinnon; André Nussenzweig
Journal:  Mol Cell       Date:  2021-04-14       Impact factor: 19.328

8.  Cytoplasmic ADP-ribosylation levels correlate with markers of patient outcome in distinct human cancers.

Authors:  Fabio Aimi; Holger Moch; Peter Schraml; Michael O Hottiger
Journal:  Mod Pathol       Date:  2021-03-19       Impact factor: 7.842

9.  Exploiting DNA repair pathways for tumor sensitization, mitigation of resistance, and normal tissue protection in radiotherapy.

Authors:  Jac A Nickoloff; Lynn Taylor; Neelam Sharma; Takamitsu A Kato
Journal:  Cancer Drug Resist       Date:  2021-06-19

10.  Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.

Authors:  Ke Cong; Min Peng; Arne Nedergaard Kousholt; Wei Ting C Lee; Silviana Lee; Sumeet Nayak; John Krais; Pamela S VanderVere-Carozza; Katherine S Pawelczak; Jennifer Calvo; Nicholas J Panzarino; John J Turchi; Neil Johnson; Jos Jonkers; Eli Rothenberg; Sharon B Cantor
Journal:  Mol Cell       Date:  2021-07-02       Impact factor: 19.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.